石药创新(300765)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300765 石药创新

已收盘 06-18 15:00:00

{"stockData":{"symbol":"300765","market":"SZ","secType":"STK","nameCN":"石药创新","latestPrice":23.95,"timestamp":1781766204000,"preClose":24.59,"halted":0,"volume":15015524,"delay":0,"changeRate":-0.026,"floatShares":1405000000,"shares":1405000000,"eps":-0.2194,"marketStatus":"已收盘","change":-0.64,"latestTime":"06-18 15:00:00","open":24.36,"high":24.99,"low":23.81,"amount":364000000,"amplitude":0.048,"askPrice":23.95,"askSize":4,"bidPrice":23.94,"bidSize":11,"shortable":0,"etf":0,"ttmEps":-0.2194,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782091800000},"marketStatusCode":5,"adr":0,"adjPreClose":24.59,"symbolType":"stock","openAndCloseTimeList":[[1781746200000,1781753400000],[1781758800000,1781766000000]],"highLimit":27.05,"lowLimit":22.13,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1404592944,"isCdr":false,"pbRate":13.4,"roa":"--","roe":"--","epsLYR":-0.1731,"committee":0.257143,"marketValue":33640000000,"turnoverRate":0.0107,"status":1,"floatMarketCap":33640000000},"requestUrl":"/m/hq/s/300765","defaultTab":"news","newsList":[{"id":"2645272095","title":"每周股票复盘：石药创新（300765）拟更名并推进多项新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2645272095","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645272095?lang=zh_cn&edition=full","pubTime":"2026-06-21 02:14","pubTimestamp":1781979252,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，石药创新报收于23.95元，较上周的23.23元上涨3.1%。本周，石药创新6月17日盘中最高价报26.21元。第七届董事会第二次会议决议公告石药创新制药股份有限公司于2026年6月16日召开第七届董事会第二次会议，审议通过《关于变更证券简称的议案》。董事会同意将证券简称由“新诺威”变更为“石药创新”。截至公告日，公司使用闲置募集资金进行现金管理尚未到期金额为3.4亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062100000561.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644619330","title":"新股消息 | 石药创新(300765.SZ)二次递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2644619330","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644619330?lang=zh_cn&edition=full","pubTime":"2026-06-20 07:48","pubTimestamp":1781912933,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所6月18日披露，石药创新制药股份有限公司(简称：石药创新(300765.SZ))递表港交所主板，中信证券为其独家保荐人。该公司曾于2025年12月10日向港交所递交上市申请。招股书显示，根据弗若斯特沙利文资料，自2020年至2025年，按收入和出货量计，石药创新始终保持着全球最大化学合成咖啡因生产商地位，公司主要生产用作功能性饮料中的食品添加剂的咖啡因。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","HEXmain","300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644098702","title":"石药创新最新公告：控股子公司司库奇尤单抗注射液上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2644098702","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644098702?lang=zh_cn&edition=full","pubTime":"2026-06-18 18:30","pubTimestamp":1781778623,"startTime":"0","endTime":"0","summary":"石药创新(300765.SZ)公告称，公司控股子公司石药集团巨石生物制药有限公司的司库奇尤单抗注射液上市申请已获得国家药监局受理。该药物为全人源IgG1单克隆抗体，用于治疗银屑病、强直性脊柱炎等疾病，是原研药可善挺的生物类似物。研究显示其与原研药在有效性、安全性等方面高度相似。药品需经审评批准后方可上市销售，存在审批风险。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800033165.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643585817","title":"新诺威(300765.SZ)证券简称变更为“石药创新”","url":"https://stock-news.laohu8.com/highlight/detail?id=2643585817","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643585817?lang=zh_cn&edition=full","pubTime":"2026-06-16 17:20","pubTimestamp":1781601606,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新诺威(300765.SZ)发布公告，自2024年以来，公司依托巨石生物加速向创新型生物医药企业转型，重点布局抗体药物、ADC及mRNA疫苗等前沿技术平台，稳步推进生物药管线研发与产业化，产品覆盖肿瘤、代谢、自身免疫疾病及感染性疾病等多个治疗领域，已形成“研发—生产—商业化”的完整产业链。为进一步强化企业形象与品牌价值，使证券简称与公司主营业务及战略定位相匹配，公司将证券简称由“新诺威”变更为“石药创新”。新证券简称的启用日期为2026年6月17日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","161027","300765","HK0000165453.HKD","LU0326950275.SGD","BK1191","LU1152091754.HKD","BK1515","SG9999004220.SGD","LU0315179316.USD","LU1226288253.USD","LU1807302812.USD","IE0008369823.USD","LU1226287529.USD","LU0067412154.USD","IE00BZ08YS42.EUR","LU1008478684.HKD","BK0226","LU0880133367.SGD","LU0314109678.HKD","LU1152091168.USD","LU1993786604.SGD","IE00B543WZ88.USD","IE00BZ08YT58.USD","LU1951186391.HKD","LU1960683339.HKD","LU1328277881.USD","IE00B031HY20.USD","LU1226287792.SGD","LU1813983027.USD","BK1521","IE0008368742.USD","LU0501845795.SGD","LU1226287875.USD","LU1226288170.HKD","LU0140636845.USD","LU2039709279.SGD","LU0072913022.USD","01093","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643727440","title":"新诺威最新公告：控股子公司SYS6041获药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2643727440","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643727440?lang=zh_cn&edition=full","pubTime":"2026-06-15 17:53","pubTimestamp":1781517216,"startTime":"0","endTime":"0","summary":"新诺威(300765.SZ)公告称，控股子公司石药集团巨石生物制药有限公司收到国家药监局核准签发关于SYS6041(叶酸受体ADC)的《药物临床试验批准通知书》，同意开展联合用药用于治疗卵巢癌的临床试验。SYS6041是一种靶向叶酸受体α的抗体-药物偶联物，潜在适应症为妇科肿瘤和肺癌等实体瘤。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500023179.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643799122","title":"6月15日新诺威涨6.50%，工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2643799122","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643799122?lang=zh_cn&edition=full","pubTime":"2026-06-15 16:52","pubTimestamp":1781513526,"startTime":"0","endTime":"0","summary":"证券之星消息，6月15日新诺威涨6.50%，收盘报24.74元，换手率1.06%，成交量14.89万手，成交额3.61亿元。重仓新诺威的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共43家，其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500020489.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159891","BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642441408","title":"新股消息 | 石药创新(300765.SZ)港股IPO招股书失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2642441408","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642441408?lang=zh_cn&edition=full","pubTime":"2026-06-10 11:18","pubTimestamp":1781061490,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，石药创新制药股份有限公司于2025年12月10日所递交的港股招股书满6个月，于2026年6月10日失效，递表时中信证券为其独家保荐人。目前已在抗体药物、抗体偶联药物及mRNA疫苗领域累积了深厚技术实力。截至最后实际可行日期，该公司拥有15个处于临床或后期开发阶段的在研药物，其中包括9款ADC在研药物和1款mRNA疫苗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452403.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0315179316.USD","BK1521","LU1152091168.USD","IE0008369823.USD","IE00B543WZ88.USD","01093","LU1008478684.HKD","IE0008368742.USD","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","LU1813983027.USD","300765","LU1951186391.HKD","LU2039709279.SGD","LU0326950275.SGD","LU0072913022.USD","BK1191","LU0140636845.USD","LU0880133367.SGD","LU1226287792.SGD","LU1993786604.SGD","LU1226287529.USD","LU1960683339.HKD","VXUS","LU0314109678.HKD","LU1152091754.HKD","IE00BZ08YS42.EUR","BK4585","LU0501845795.SGD","IE00B031HY20.USD","SG9999004220.SGD","LU1328277881.USD","HK0000165453.HKD","LU1226287875.USD","BK4588","LU0067412154.USD","LU1226288170.HKD","IE00B5MMRT66.SGD","IPOS","LU1226288253.USD","BK1515","BK0226","LU1807302812.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641210054","title":"6月8日新诺威跌5.22%，工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641210054","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641210054?lang=zh_cn&edition=full","pubTime":"2026-06-08 17:03","pubTimestamp":1780909389,"startTime":"0","endTime":"0","summary":"证券之星消息，6月8日新诺威跌5.22%，收盘报23.6元，换手率0.84%，成交量11.74万手，成交额2.81亿元。重仓新诺威的前十大公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共43家，其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800022719.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226","159891"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641038111","title":"新诺威：公司与阿斯利康的合作正常推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2641038111","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641038111?lang=zh_cn&edition=full","pubTime":"2026-06-05 18:00","pubTimestamp":1780653638,"startTime":"0","endTime":"0","summary":"证券之星消息，新诺威(300765)06月05日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，请问公司和阿斯利康的合作是否正常进行？谢谢。新诺威回复：您好，感谢您对公司的关注，公司与阿斯利康的合作正常推进中，谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500031259.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641119402","title":"6月5日新诺威现1197.69万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2641119402","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641119402?lang=zh_cn&edition=full","pubTime":"2026-06-05 17:33","pubTimestamp":1780651981,"startTime":"0","endTime":"0","summary":"证券之星消息，6月5日新诺威发生大宗交易，交易数据如下：大宗交易成交价格24.9元，成交48.1万股，成交金额1197.69万元，买方营业部为机构专用，卖方营业部为机构专用。近三个月该股共发生6笔大宗交易，合计成交1.52万手。该股近期无解禁股上市。截至2026年6月5日收盘，新诺威(300765)报收于24.9元，下跌1.66%，换手率0.66%，成交量9.3万手，成交额2.36亿元。该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500030305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640970956","title":"新诺威：截至2026年5月29日股东数为22,549户","url":"https://stock-news.laohu8.com/highlight/detail?id=2640970956","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640970956?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:15","pubTimestamp":1780478119,"startTime":"0","endTime":"0","summary":"证券之星消息，新诺威(300765)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，请问截止到5.29日的股东人数是多少？谢谢新诺威回复：您好，感谢您对公司的关注，截至2026年5月29日，公司合并普通账户和融资融券信用账户股东数为22,549户，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300034792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640959970","title":"新诺威：截至2026年5月29日股东数为22,549户","url":"https://stock-news.laohu8.com/highlight/detail?id=2640959970","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640959970?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:15","pubTimestamp":1780478113,"startTime":"0","endTime":"0","summary":"证券之星消息，新诺威(300765)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司最新股东人数？谢谢！新诺威回复：您好，感谢您对公司的关注，截至2026年5月29日，公司合并普通账户和融资融券信用账户股东数为22,549户，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300034782.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640602947","title":"股市必读：6月2日新诺威发生2笔大宗交易 成交金额1046.43万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640602947","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640602947?lang=zh_cn&edition=full","pubTime":"2026-06-03 01:25","pubTimestamp":1780421112,"startTime":"0","endTime":"0","summary":"截至2026年6月2日收盘，新诺威报收于25.56元，下跌1.5%，换手率0.81%，成交量11.42万手，成交额2.88亿元。大宗交易6月2日新诺威发生2笔大宗交易，成交金额1046.43万元。公司公告汇总关于控股子公司SYS6043在2026年美国临床肿瘤学会年会公布研究成果的公告石药创新制药控股子公司巨石生物在2026年美国临床肿瘤学会年会上以口头报告形式公布了其自主研发的B7-H3靶向ADC药物SYS6043的I期临床研究数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300001685.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640499569","title":"新诺威（300765）披露控股子公司SYS6043在ASCO年会公布I期临床研究数据，6月2日股价下跌1.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640499569","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640499569?lang=zh_cn&edition=full","pubTime":"2026-06-02 22:21","pubTimestamp":1780410084,"startTime":"0","endTime":"0","summary":"截至2026年6月2日收盘，新诺威报收于25.56元，较前一交易日下跌1.5%，最新总市值为359.01亿元。近日，新诺威披露《关于控股子公司SYS6043在2026年美国临床肿瘤学会年会公布研究成果的公告》。公告显示，石药创新制药控股子公司巨石生物在2026年美国临床肿瘤学会年会上以口头报告形式公布了其自主研发的B7-H3靶向ADC药物SYS6043的I期临床研究数据。各瘤种中乳腺癌ORR最高，达56.8%。目前公司正推进卵巢癌、乳腺癌及小细胞肺癌的进一步研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200047309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640913218","title":"新诺威(300765.SZ)：子公司SYS6043在2026年美国临床肿瘤学会年会公布研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2640913218","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640913218?lang=zh_cn&edition=full","pubTime":"2026-06-02 15:59","pubTimestamp":1780387160,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新诺威 发布公告，公司控股子公司石药集团巨石生物制药有限公司在2026年5月29日-6月2日于芝加哥举行的2026年美国临床肿瘤学会年会中，以口头报告形式公布SYS6043的I期临床研究数据。公告显示，SYS6043是一款新型B7-H3靶向ADC。研究结果表明，SYS6043有望成为多个瘤种的治疗选择。SYS6043在多个瘤种的患者中均展现出良好的抗肿瘤活性。公司目前正在积极推进卵巢癌、乳腺癌及小细胞肺癌的相关研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449038.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640795503","title":"新诺威：截至2026年5月20日股东数为22,380户","url":"https://stock-news.laohu8.com/highlight/detail?id=2640795503","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640795503?lang=zh_cn&edition=full","pubTime":"2026-06-01 19:06","pubTimestamp":1780311971,"startTime":"0","endTime":"0","summary":"证券之星消息，新诺威(300765)06月01日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司截止5月22号股东人数是多少？新诺威回复：您好，感谢您对公司的关注，截至2026年5月20日，公司合并普通账户和融资融券信用账户股东数为22,380户，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100033375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640955030","title":"新诺威：截至2026年5月20日股东数为22,380户","url":"https://stock-news.laohu8.com/highlight/detail?id=2640955030","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640955030?lang=zh_cn&edition=full","pubTime":"2026-06-01 19:06","pubTimestamp":1780311967,"startTime":"0","endTime":"0","summary":"证券之星消息，新诺威(300765)06月01日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，请问截止到5月20日，公司股东人数是多少？新诺威回复：您好，感谢您对公司的关注，截至2026年5月20日，公司合并普通账户和融资融券信用账户股东数为22,380户，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100033370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639629107","title":"新诺威最新公告：控股子公司收到阿斯利康4.2亿美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2639629107","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639629107?lang=zh_cn&edition=full","pubTime":"2026-05-29 18:20","pubTimestamp":1780050019,"startTime":"0","endTime":"0","summary":"新诺威(300765.SZ)公告称，公司控股子公司巨石生物于2026年5月29日收到阿斯利康支付的4.2亿美元首付款。该款项基于双方于2026年1月29日签署的战略合作与授权协议，旨在推进创新多肽分子发现和长效递送产品的开发。此次收款将充实巨石生物现金储备，有利于管线研发及战略布局，预计对公司业绩和财务状况产生积极影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900035289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637391153","title":"新诺威(300765.SZ)子公司乌司奴单抗注射液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2637391153","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637391153?lang=zh_cn&edition=full","pubTime":"2026-05-22 15:52","pubTimestamp":1779436338,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新诺威 发布公告，公司控股子公司石药集团巨石生物制药有限公司于近日收到国家药品监督管理局核准签发的乌司奴单抗注射液《药品注册证书》。乌司奴单抗通过阻断与细胞表面受体链IL-12R β 1的相互作用，破坏IL-12和IL-23介导的信号传导和细胞因子的级联反应，从而有效缓解疾病症状、持续改善病情，为患者带来长期临床获益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445012.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"新诺威(300765.SZ)子公司乌司奴单抗注射液获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637085878","title":"股市必读：新诺威（300765）5月20日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2637085878","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637085878?lang=zh_cn&edition=full","pubTime":"2026-05-21 04:16","pubTimestamp":1779308173,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，新诺威报收于29.52元，下跌1.27%，换手率0.56%，成交量7.87万手，成交额2.33亿元。董秘最新回复投资者： 请问截至2026年4月30日公司的股东总数是多少？谢谢董秘： 您好，感谢您对公司的关注，截至2026年4月30日，公司合并普通账户和融资融券信用账户股东数为22,425户，谢谢！交易信息汇总资金流向5月20日主力资金净流出56.86万元；游资资金净流出261.21万元；散户资金净流入318.06万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100004968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1782025159606,"stockEarnings":[{"period":"1week","weight":-0.0008},{"period":"1month","weight":-0.199},{"period":"3month","weight":-0.2059},{"period":"6month","weight":-0.3096},{"period":"1year","weight":-0.5722},{"period":"ytd","weight":-0.336}],"compareEarnings":[{"period":"1week","weight":0.026},{"period":"1month","weight":-0.019},{"period":"3month","weight":0.0337},{"period":"6month","weight":0.0514},{"period":"1year","weight":0.2071},{"period":"ytd","weight":0.0306}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"石药创新制药股份有限公司","boardCode":"AI0014","boardName":"食品制造业","stockholders":"22549人(较上一季度增加0.76%)","perCapita":"62290股","listingDate":"2019-03-22","address":"河北省石家庄市栾城区张举路62号","registeredCapital":"140459万元","survey":"　　石药创新制药股份有限公司的主营业务是生物制药、功能性原料及保健食品的研发、生产与商业化。公司的主要产品是恩朗苏拜单抗注射液、注射用奥马珠单抗注射液、咖啡因、阿卡波糖、果维康维生素C咀嚼片。公司是国内首批实现mRNA疫苗产业化、ADC与抗体药物管线布局最完整的创新型生物药企业之一，已发展成为集源头创新、临床转化、规模生产与国际商业化于一体的高新技术企业。","listedPrice":24.47},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药创新(300765)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药创新(300765)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药创新,300765,石药创新股票,石药创新股票老虎,石药创新股票老虎国际,石药创新行情,石药创新股票行情,石药创新股价,石药创新股市,石药创新股票价格,石药创新股票交易,石药创新股票购买,石药创新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石药创新(300765)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石药创新(300765)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}